Skip to main content
Clinical Trials/NCT02632149
NCT02632149
Unknown
Early Phase 1

The Clinical Research on PINS Vagus Nerve Stimulator for Treatment of Lennox-Gastaut in Children

Beijing Pins Medical Co., Ltd5 sites in 1 country31 target enrollmentOctober 2016

Overview

Phase
Early Phase 1
Intervention
Not specified
Conditions
Lennox-Gastaut Syndrome
Sponsor
Beijing Pins Medical Co., Ltd
Enrollment
31
Locations
5
Primary Endpoint
Changes in seizure frequency from baseline to the seizure count evaluation period 6 month
Last Updated
9 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the clinical effectiveness of PINS vagus nerve stimulatior in children with Lennox-Gastaut Syndrome.

Registry
clinicaltrials.gov
Start Date
October 2016
End Date
October 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 3-14 year
  • Lennox - Gastaut syndrome diagnostic standard
  • Regular drug treatment is invalid
  • Antiepileptic drug stability in recent 3 months
  • Good health except epilepsy
  • Patients or his(her) familyscould understand this method and sign the informed consent
  • Patients with good compliance and could complete postoperative follow-up.

Exclusion Criteria

  • Results of MRI remind epilepsy caused by intracranial space-occupying lesions
  • Had epileptic foci excision surgery or corpus callosum
  • The vagus nerve lesion and damage
  • Tumor, cardiopulmonary anomaly, progressive neurological diseases, asthma, mental disease,peptic ulcer,diabetes Type 1,bad health etc, and other surgical contraindication
  • Participated in other clinical drug test subjects within three months
  • The researchers think that is not suitable for participants'

Outcomes

Primary Outcomes

Changes in seizure frequency from baseline to the seizure count evaluation period 6 month

Time Frame: 6 month of stimulation

Secondary Outcomes

  • Changes in seizure frequency from baseline to the seizure count evaluation period(1,3,6,months of stimulation)
  • Change from Baseline in the Engel and McHugh description(At 1,3,6 months)
  • Overall WISC Score in Patients from Baseline(Mean change from baseline WISC Overall Score at 1,3,6months)

Study Sites (5)

Loading locations...

Similar Trials